The A 2A agonist CGS 21680 [2 mM] decreased the mean amplitude of both the ERG b-wave of dark adapted (298.2±21.5 µV to 212.5±19.3 µV; p = 0.005) and light adapted eyes (124.3±17.7 µV to 87.8±11.2 µV; p = 0.045).
A 2A samverkarinn CGS 21680 [2 mM] olli minnkun á b-bylgjunni í rökkursaðlögðum (298.2±21.5 µV í 212±19.3 µV; p = 0.005) og ljósaðlögðum augum (124.3±17.7 µV í 87.8±11.2 µV; p = 0.045).